Clinical Trials

MainTitle

Early Versus Delayed Routine HIV Testing in Connecticut Jails (SWAB)

This study has been completed
Sponsor
Yale University

Collaborator
National Institute on Drug Abuse (NIDA)

Information provided by (Responsible Party)
Yale University
ClinicalTrials.gov Identifier
NCT00624247

First received: February 18, 2008
Last updated: October 16, 2014
Last Verified: February 2009
History of Changes
Purpose

Purpose

The objective of this non-randomized, controlled, trial is to evaluate the optimal time to approach newly incarcerated jail inmates for routine opt-out HIV testing in a manner that maximizes the number of individuals able to demonstrate capacity to consent and willingness to receive HIV testing.

Condition Intervention Phase
HIV Infections

Other : routine HIV testing
Early Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Early Versus Delayed Routine HIV Testing in Connecticut Jails

Further study details as provided by Yale University:

Primary Outcome Measures

  • The proportion of individuals in each testing group who are orally swabbed and consented to rapid HIV testing. [ Time Frame: Immediately, the following evening, and 7 days post-entry ]

Enrollment: 621
Study Start Date: August 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Other: Immediate
Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
Other: routine HIV testing

Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.

Other: Following Day
Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
Other: routine HIV testing

Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.

Other: Delayed
Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
Other: routine HIV testing

Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.

Detailed Description:

Primary outcome: proportion of individuals in each assigned group that agree to be swabbed for HIV testing and are able to consent to the study.
The prevalence of HIV infection in the United States is four times greater in correctional settings compared to the general population. Because prisons and jails house a population facing a disproportionate share of the burden of HIV infection, these facilities serve as important sites for the testing and treatment of HIV. The Center for Disease Control and Prevention's recent recommendations to implement routine opt-out HIV testing in all healthcare settings presents an important challenge and opportunity to correctional institutions. By effectively implementing routine opt-out testing, correctional facilities can expand HIV testing to one of society's most at-risk populations. Subsequently, testing can lead to appropriate access to counseling and treatment both within the correctional setting and upon release into the community.
Although jails interact with a larger number of individuals at risk for HIV infection than do prisons, they also pose unique logistical and health-related constraints in several important ways that impact HIV testing strategies. Jail populations experience short periods of incarceration and high rates of turnover with many-fold greater admissions and discharges. Jails also house individuals with higher rates of acute intoxication from psychoactive drugs, uncontrolled mental illness, and suicidal behavior. The suicide rate in jails is three times that in state prisons; nearly a quarter of these suicides take place within the first 48 hours of admission. Furthermore, the individuals who enter jails have higher recent risk behaviors for HIV than those in prisons.
Given these considerations, a major challenge to implementing routine opt-out HIV testing in jails is choosing the optimal time to conduct testing. The timing of delivering non-emergent, traumatically emotional health information (such as a preliminary positive result in an asymptomatic patient) must be carefully considered. Recently incarcerated inmates might be too intoxicated or psychologically distressed to demonstrate capacity to consent to or opt out of routine testing, and may be unprepared to consider and respond to the consequences of a preliminary positive HIV test result. Likewise, the challenge with postponing testing is that many individuals experience very short stays in jail, with approximately one-third leaving within 48 hours, followed by further attrition daily for the first week and may lose the opportunity for getting life-saving information in a timely manner.
Therefore, the objective of this study is to evaluate the optimal time to approach newly incarcerated jail inmates for routine opt-out HIV testing in a manner that maximizes the number of individuals able to demonstrate capacity to consent and willingness to receive HIV testing.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria:

  • All newly incarcerated inmates will be eligible for this study.

Exclusion Criteria:

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00624247

Locations

United States, Connecticut
New Haven Community Correctional Center
New Haven, Connecticut, United States, 06511
York Correctional Institution
Niantic, Connecticut, United States, 06357

Sponsors and Collaborators

Yale University
National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator: Frederick L Altice, MD Yale University AIDS Program
More Information

More Information


Responsible Party: Yale University  
ClinicalTrials.gov Identifier: NCT00624247   History of Changes  
Other Study ID Numbers: 0705002664  
Study First Received: February 18, 2008  
Last Updated: October 16, 2014  

Keywords provided by Yale University:

routine HIV testing
jails
criminal justice system
substance abuse
mental illness
HIV

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on November 22, 2017
This information is provided by ClinicalTrials.gov.